ABC294640 (Opaganib)
Cholangiocarcinoma (Bile Duct Cancer)
Key Facts
About Apogee Biotechnology
Apogee Biotechnology is a clinical-stage biotech developing first-in-class, oral sphingosine kinase (SK) inhibitors, with opaganib (ABC294640) as its lead asset. The company's platform targets a key enzyme in sphingolipid metabolism implicated in cancer proliferation, inflammation, and viral replication. Financed primarily through NIH SBIR and state grants, Apogee is advancing opaganib in Phase II trials for cholangiocarcinoma and prostate cancer, and has explored its use in COVID-19 due to anti-viral and anti-inflammatory properties.
View full company profileAbout Apogee Biotechnology
Apogee Biotechnology is a clinical-stage biotech developing first-in-class, oral sphingosine kinase (SK) inhibitors, with opaganib (ABC294640) as its lead asset. The company's platform targets a key enzyme in sphingolipid metabolism implicated in cancer proliferation, inflammation, and viral replication. Financed primarily through NIH SBIR and state grants, Apogee is advancing opaganib in Phase II trials for cholangiocarcinoma and prostate cancer, and has explored its use in COVID-19 due to anti-viral and anti-inflammatory properties.
View full company profileAbout Apogee Biotechnology
Apogee Biotechnology is a clinical-stage biotech developing first-in-class, oral sphingosine kinase (SK) inhibitors, with opaganib (ABC294640) as its lead asset. The company's platform targets a key enzyme in sphingolipid metabolism implicated in cancer proliferation, inflammation, and viral replication. Financed primarily through NIH SBIR and state grants, Apogee is advancing opaganib in Phase II trials for cholangiocarcinoma and prostate cancer, and has explored its use in COVID-19 due to anti-viral and anti-inflammatory properties.
View full company profileTherapeutic Areas
Other Cholangiocarcinoma (Bile Duct Cancer) Drugs
| Drug | Company | Phase |
|---|---|---|
| certepetide (LSTA1) | Lisata Therapeutics | Phase 2a |